Categories: News

Philips partners with Orbita to develop conversational voice and chatbot applications to complement its telehealth solutions

March 29, 2021

Partnership to create AI-based virtual assistants with the human touch needed for effective remote patient engagement

Amsterdam, the Netherlands and Boston, U.S. – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Orbita Inc., an innovative provider of conversational artificial intelligence (AI) solutions for healthcare, today announced a partnership agreement to co-create next-generation conversational virtual assistants for Philips’ consumer health and patient support applications. The joint development agreement will see Orbita’s technology rolled out to digital health applications that enhance the patient experience and increase efficiency throughout the health continuum.

Orbita, a U.S.-based company, provides healthcare, life-science, and medical technology organizations with HIPAA-compliant chatbots and voice assistants for ‘digital front door’ applications, remote and in-facility patient support, pre- and post-visit outreach, and other healthcare applications. Its conversational platform allows developers and non-technical staff to quickly build and easily manage cloud-based virtual assistants that are seamlessly deployable to smart speakers, web and mobile chat apps, short message service (SMS) and interactive voice response (IVR) services, as well as custom devices.

“With the acceleration in the adoption of telehealth during the COVID-19 pandemic, AI-enabled voice services, virtual assistants and chatbots are already playing an enabling role in driving 24/7 access to healthcare, enhancing patient engagement, and improving clinical efficiency,” said Henk van Houten, Chief Technology Officer and Head of Philips Research. “Orbita is a not only a leader and innovator in voice and chat-powered virtual assistants that deliver the human touch needed in healthcare, but also a company that can keep up with the rapid pace of telehealth innovation that Philips is determined to pursue.”

“We are extremely excited to be expanding our partnership with Philips, one of the largest and most innovative digital health technology companies in the world,” said Nathan Treloar, President and Chief Operating Officer at Orbita. “Philips’ presence in the industry means they are at the forefront of healthcare’s most demanding challenges, where the greatest opportunities exist to apply the unique capabilities of Orbita’s products and solutions.”

Philips believes that AI has the potential to improve people’s lives across the health continuum – from healthy living and prevention to diagnosis, treatment, and home care – provided it is applied with a deep understanding of people’s lives, and the clinical and operational context in which healthcare providers operate. Its partnership with Orbita, a company that has a proven track record of successfully applying AI-enabled conversational virtual assistants in healthcare applications, is part of Philips’ overall strategy to leverage cutting-edge AI wherever it can help deliver on the Quadruple Aim of healthcare. Examples where Philips is already using AI can be found in its personal health, diagnosis and treatment, and connected care offerings. Examples of Orbita’s solutions include patient acquisition and engagement portals, virtual bedside assistants, and virtual care continuity assistants.

Philips owns a minority interest in Orbita through its Health Technology Venture Fund since May of 2020. Philips Health Technology Ventures manages a business-agnostic digital health fund that invests in, and partners with, promising healthcare informatics and health technology start-up companies to accelerate their growth and extend their reach. Active partnerships, such as the one announced today with Orbita, are an essential part of Philips’ goal to develop integrated solutions that enable healthcare providers to deliver on the Quadruple Aim – better health outcomes, better patient and staff experiences, and lower cost of care.

For further information, please contact:

For Philips:
Ben Zwirs
Philips Global Press Office
Tel.: +31 6 1521 3446
E-mail: ben.zwirs@philips.com

For Orbita Inc.:
Julia Searcy
MERGE
Tel.: +1  678.879.1929
E-mail:  jsearcy@mergeworld.com

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2020 sales of EUR 19.5 billion and employs approximately 82,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

About Orbita Inc.
Orbita’s award-winning, HIPAA-compliant conversational AI platform powers voice and chat solutions for healthcare and life sciences organizations that improve patient engagement, increase clinical efficiency, and improve outcomes. Customers include innovative organizations like Mass General Brigham, Mayo Clinic, Amwell, Yale New Haven Hospital, Cancer Treatment Centers of America, University of Chicago Medicine, and a portfolio of pharmaceutical clients. Partners include Cognizant, Deloitte, Pariveda, and ServiceNow. Find us at orbita.ai, contact us at hello@orbita.ai.

Staff

Recent Posts

Daily Fit Notes Rolls Out Affordable Fitness Solutions for the Modern Lifestyle

Daily Fit Notes, founded by Justin Brey in New York, launches a text-based subscription fitness…

1 day ago

WillowWood Rebrand by DD.NYC Wins Gold Anthem Award for Product and Innovation in 2024 Rebrand

MT. STERLING, Ohio, Dec. 20, 2024 /PRNewswire/ -- WillowWood, a global leader in prosthetic solutions,…

2 days ago

Quantum Biopharma Announces Closing of Second Tranche

TORONTO, ON / ACCESSWIRE / December 20, 2024 / Quantum BioPharma Ltd. (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) ("Quantum BioPharma"…

2 days ago

Glow Lifetech Announces Completion of Final Payment under Swiss Pharma Share Exchange Agreement and Debt Settlement

Toronto, Ontario--(Newsfile Corp. - December 20, 2024) - Glow Lifetech Corp. (CSE: GLOW) (OTC Pink:…

2 days ago